| Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives BC Prudner, T Ball, R Rathore, AC Hirbe Neuro-Oncology Advances, 2019 | 65 | 2019 |
| Pathogenesis and current treatment of osteosarcoma: perspectives for future therapies R Rathore, BA Van Tine Journal of clinical medicine 10 (6), 1182, 2021 | 61 | 2021 |
| Arginine Starvation and Docetaxel Induce c-Myc–Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors BC Prudner, R Rathore, AM Robinson, A Godec, SF Chang, WG Hawkins, ... Clinical Cancer Research 25 (16), 5122-5134, 2019 | 55 | 2019 |
| Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma R Rathore, KE Caldwell, C Schutt, CB Brashears, BC Prudner, ... Cell Reports 34 (4), 108678, 2021 | 42 | 2021 |
| Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma AM Robinson, R Rathore, NJ Redlich, DR Adkins, T VanArsdale, ... Cell death & disease 10 (11), 1-13, 2019 | 38 | 2019 |
| Targeted delivery of gold nanoparticle contrast agents for reporting gene detection by magnetic resonance imaging LF Vistain, MW Rotz, R Rathore, AT Preslar, TJ Meade Chemical Communications 52 (1), 160-163, 2016 | 34 | 2016 |
| PHGDH as a mechanism for resistance in metabolically-driven cancers R Rathore, CR Schutt, BA Van Tine Cancer Drug Resistance 3 (4), 762-774, 2020 | 31 | 2020 |
| Targeted Inhibition of Snail Activity in Breast Cancer Cells by Using a CoIII‐Ebox Conjugate LF Vistain, N Yamamoto, R Rathore, P Cha, TJ Meade ChemBioChem 16 (14), 2065-2072, 2015 | 22 | 2015 |
| Interim analysis of the phase II study: noninferiority study of doxorubicin with upfront dexrazoxane plus olaratumab for advanced or metastatic soft-tissue sarcoma BA Van Tine, AC Hirbe, P Oppelt, AE Frith, R Rathore, JD Mitchell, F Wan, ... Clinical Cancer Research 27 (14), 3854-3860, 2021 | 10 | 2021 |
| Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming CB Brashears, M Barlin, WR Ehrhardt, R Rathore, M Schultze, SC Tzeng, ... Cell Death & Disease 11 (8), 1-15, 2020 | 9 | 2020 |
| Cucurbit [6] uril as a fire retardant material G Cai, Z Matusinovic, D Yi, T Mariappan, R Shukla, R Rathore, CA Wilkie Fire and Polymers VI: New Advances in Flame Retardant Chemistry and Science …, 2012 | 2 | 2012 |
| Low Incidence of Cardiovascular Events in Patients With Metastatic Sarcoma Using Upfront Dexrazoxane and High-Dose Doxorubicin JD Mitchell, B Van Tine, AC Hirbe, P Oppelt, A Frith, R Rathore, F Wan, ... Circulation 144 (Suppl_1), A12572-A12572, 2021 | | 2021 |
| Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma R Rathore, B Van Tine Molecular & Cellular Oncology 8 (3), 1902250, 2021 | | 2021 |
| Developing a Metabolic Therapy for Osteosarcoma R Rathore, B Van Tine Oncology Times 43 (8), 1-4, 2021 | | 2021 |
| Targeting the PHGDH-mTOR Metabolic Axis in Osteosarcoma R Rathore | | 2021 |
| Preclinical justification for the Phase II clinical trial ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma BC Prudner, R Rathore, A Godec, SF Chang, A Hirbe, BA Van Tine CANCER RESEARCH 79 (13), 2019 | | 2019 |
